Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Apr 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients.

Some background

B cells are a type of cell of the immune system. Some lymphomas and leukemias such as non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL) affect these cells. Targeted therapies such as Bruton's tyrosine kinase (BTK) inhibitors have improved the outcomes of patients with B-cell blood cancers. However, many patients develop resistance or intolerable side effects to current BTK inhibitors. Therefore, newer agents are needed for these patients. 

Pirtobrutinib is a new BTK inhibitor in clinical trials. The safety and effectiveness of pirtobrutinib in patients with previously treated B-cell leukemia/lymphoma are still under investigation.

Methods & findings

323 patients with leukemia/lymphoma were enrolled in the study. All patients had at least 2 previous lines of therapy. Pirtobrutinib was given to all patients. Seven dose levels were tested as tablets once daily in 28-day cycles. The recommended dose was 200 mg per day. The average follow-up period was 5-6 months.

63% of the patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) had a response to pirtobrutinib therapy. 52% of patients with mantle cell lymphoma (MCL) and 68% with Waldenström macroglobulinemia (WM; lymphoplasmacytic lymphoma) had a response to pirtobrutinib. This was similar for patients that had previously been treated with another BTK inhibitor and those who were not.

88% of patients with CLL/SLL, 57% with MCL, and 77% with WM were still on pirtobrutinib treatment at follow-up.

Most side effects were mild. The most common side effects were fatigue (20%) and diarrhea (17%).

The bottom line

The authors found that pirtobrutinib was effective and safe for the treatment of B-cell leukemia/lymphoma.

The fine print

This was a small phase 1/2 clinical trial. The follow-up period was very short. Additional studies are needed to determine whether the efficacy of pirtobrutinib is long-term. This study was funded by Loxo Oncology, the manufacturer of pirtobrutinib.

Published By :

Lancet (London, England)

Date :

Mar 06, 2021

Original Title :

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

click here to get personalized updates